Insider · CIK 0001750050
Mayukh Sukhatme
Files at ROIV (Roivant Sciences Ltd.). First filing Dec 20, 2024, latest Feb 11, 2026.
Mayukh Sukhatme files SEC Form 4 as director and president at ROIV (Roivant Sciences Ltd.). Since Dec 20, 2024, Mayukh Sukhatme has reported 0 open-market buys worth $0 and 5 open-market sells worth $54M, the latest filed on Feb 11, 2026.
A track record needs three past buys with six months of prices behind them; Mayukh Sukhatme has 0, so none is measured yet.
The newest scored trade: sold $9.0M of ROIV on Feb 9, 2026, filed Feb 11, 2026, scored 45 (moderate). In the last 12 months: 0 buys worth $0 and 3 sells worth $39M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ROIV: Roivant Sciences Ltd.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Roivant Sciences Ltd. | $9.0M 339,441 shares | -2% | +205% from low0% from high | |
| 45Moderate | Roivant Sciences Ltd. | $29M 1,330,868 shares | -7% | +139% from low-5% from high | |
| 40Moderate | Roivant Sciences Ltd. | $620k 26,831 shares | -0% | +150% from low-1% from high | |
| 33Weak | Roivant Sciences Ltd. | $11M 886,237 shares | -5% | - | |
| 33Weak | Roivant Sciences Ltd. | $5.0M 412,584 shares | -2% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 26, 2024 | ROIV Roivant Sciences Ltd. | 185,946 0.03% of outstanding | $2.2M | Dec 24, 2024 | $5.1M |
| Dec 26, 2024 | ROIV Roivant Sciences Ltd. | 689,495 0.09% of outstanding | $8.3M | Dec 26, 2024 | $7.3M |
| Dec 23, 2024 | ROIV Roivant Sciences Ltd. | 10,796 0.00% of outstanding | $130k | Dec 23, 2024 | $5.0M |
| Dec 18, 2024 | ROIV Roivant Sciences Ltd. | 412,584 0.06% of outstanding | $5.0M | Dec 18, 2024 | none |
Transactions
Every row this insider has filed, 30 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | ROIV Roivant Sciences Ltd. | FTax withholding Common Shares | -46,879 | $36.57 | $1.7M | 18,583,860 | 11 d ago |
| Feb 9, 2026 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +651,558 | $12.68 | $8.3M | 19,488,105 | Feb 11, 2026 |
| Feb 9, 2026 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -339,441 | $26.47 | $9.0M | 19,148,664 | Feb 11, 2026 |
| Feb 9, 2026 | ROIV Roivant Sciences Ltd. | JOther Common Shares | -312,117 | $26.47 | $8.3M | 18,836,547 | Feb 11, 2026 |
| Feb 9, 2026 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -651,558 | $0.00 | $0 | 0 | Feb 11, 2026 |
| Dec 29, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +748,358 | $12.68 | $9.5M | 19,584,905 | Dec 31, 2025 |
| Dec 29, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -311,873 | $21.74 | $6.8M | 19,273,032 | Dec 31, 2025 |
| Dec 29, 2025 | ROIV Roivant Sciences Ltd. | JOther Common Shares | -436,485 | $21.74 | $9.5M | 18,836,547 | Dec 31, 2025 |
| Dec 31, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +2,449,877 | $12.68 | $31M | 21,286,424 | Dec 31, 2025 |
| Dec 31, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -1,018,995 | $21.71 | $22M | 20,267,429 | Dec 31, 2025 |
| Dec 31, 2025 | ROIV Roivant Sciences Ltd. | JOther Common Shares | -1,430,882 | $21.71 | $31M | 18,836,547 | Dec 31, 2025 |
| Dec 29, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -748,358 | $0.00 | $0 | 555,840 | Dec 31, 2025 |
| Dec 31, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -2,449,877 | $0.00 | $0 | 95,718 | Dec 31, 2025 |
| Dec 17, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +59,513 | $12.68 | $755k | 18,896,060 | Dec 19, 2025 |
| Dec 17, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -26,831 | $23.09 | $620k | 18,869,229 | Dec 19, 2025 |
| Dec 17, 2025 | ROIV Roivant Sciences Ltd. | JOther Common Shares | -32,682 | $23.09 | $755k | 18,836,547 | Dec 19, 2025 |
| Dec 17, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Sharesderivative | -59,513 | $0.00 | $0 | 1,304,198 | Dec 19, 2025 |
| Dec 23, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +10,796 | $3.85 | $42k | 18,847,343 | Dec 26, 2024 |
| Dec 23, 2024 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -10,796 | $12.00 | $130k | 18,836,547 | Dec 26, 2024 |
| Dec 24, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +185,946 | $3.85 | $716k | 19,022,493 | Dec 26, 2024 |
| Dec 24, 2024 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -185,946 | $12.00 | $2.2M | 18,836,547 | Dec 26, 2024 |
| Dec 26, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +689,495 | $3.85 | $2.7M | 19,526,042 | Dec 26, 2024 |
| Dec 26, 2024 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -689,495 | $12.01 | $8.3M | 18,836,547 | Dec 26, 2024 |
| Dec 23, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -10,796 | $0.00 | $0 | 16,099,804 | Dec 26, 2024 |
| Dec 24, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -185,946 | $0.00 | $0 | 15,913,858 | Dec 26, 2024 |
| Dec 26, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -689,495 | $0.00 | $0 | 15,224,363 | Dec 26, 2024 |
| Dec 18, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +412,584 | $3.85 | $1.6M | 19,249,131 | Dec 20, 2024 |
| Dec 18, 2024 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -412,584 | $12.05 | $5.0M | 18,836,547 | Dec 20, 2024 |
| Dec 18, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -412,584 | $0.00 | $0 | 16,110,600 | Dec 20, 2024 |
| Dec 3, 2024 | ROIV Roivant Sciences Ltd. | JOther Common Shares | -3,651,985 | $12.21 | $45M | 18,836,547 | Dec 5, 2024 |
Questions about Mayukh Sukhatme
Answered from the filings on this page, as of the latest one.
Is Mayukh Sukhatme buying or selling?
In the last 12 months Mayukh Sukhatme reported 0 open-market buys worth $0 and 3 open-market sells worth $39M on SEC Form 4; the latest was sold $9.0M of ROIV on Feb 9, 2026. Grants, option exercises and tax withholding are not counted.
How did Mayukh Sukhatme's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mayukh Sukhatme has 0.
Where does Mayukh Sukhatme file Form 4?
Mayukh Sukhatme has filed Form 4 at ROIV (Roivant Sciences Ltd.) as President & CIO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.